TY - JOUR T1 - Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis JF - Anticancer Research JO - Anticancer Res SP - 5147 LP - 5155 DO - 10.21873/anticanres.15332 VL - 41 IS - 10 AU - TAIKO NAKAZAWA AU - YUKIYA NARITA AU - RYOSUKE KUMANISHI AU - TAKATSUGU OGATA AU - YUKI MATSUBARA AU - KAZUKI NOZAWA AU - KYOKO KATO AU - KAZUNORI HONDA AU - TOSHIKI MASUISHI AU - HIDEAKI BANDO AU - SHIGENORI KADOWAKI AU - MASASHI ANDO AU - KAZUO HARA AU - MASAHIRO TAJIKA AU - KEI MURO Y1 - 2021/10/01 UR - http://ar.iiarjournals.org/content/41/10/5147.abstract N2 - Background/Aim: Metastatic small bowel adenocarcinoma (SBA) is a rare disease with poor prognosis. This study aimed to explore the efficacy and safety of second-line chemotherapy for patients with SBA. Patients and Methods: We retrospectively reviewed the clinical characteristics of 27 metastatic patients with SBA after progression on first-line chemotherapy. The patients were divided into Cohort A, receiving second-line chemotherapy, and Cohort B, receiving best supportive care. Results: Patients in Cohort B had higher age, worse performance status, and higher neutrophil-to-lymphocyte ratio compared with those in Cohort A. Cohort A showed significantly better overall survival (OS) compared with Cohort B (median OS, 15.6 vs. 3.4 months; p=0.002). Objective response rate, disease control rate, and median progression-free survival (PFS) for Cohort A were 7%, 74%, and 5.0 months, respectively. Patients who underwent irinotecan-based chemotherapy showed longer PFS and OS compared with those who underwent taxane-based chemotherapy. No significant adverse events were reported. Conclusion: Second-line chemotherapy for metastatic SBA demonstrated clinical activity with acceptable toxicities. ER -